Cooper Companies ( (COO) ) has released its Q4 earnings. Here is a breakdown of the information Cooper Companies presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CooperCompanies, a prominent player in the medical device sector, operates through two main business units – CooperVision, a leader in the contact lens industry, and CooperSurgical, which focuses on fertility and women’s health. The company is known for its commitment to enhancing lives, with a significant global presence and a workforce of over 16,000 employees.
CooperCompanies reported strong financial results for the fourth quarter and fiscal year 2024, highlighted by record consolidated revenues and earnings per share. The company achieved a 10% increase in fourth-quarter revenue, reaching $1,018.4 million, and an 8% rise in fiscal year revenue to $3.9 billion. The GAAP EPS for the fiscal year rose by 33% to $1.96, while the non-GAAP EPS increased by 15% to $3.69, reflecting the company’s robust performance across its divisions.
Key financial metrics in the fourth quarter included a gross margin of 67% and an operating margin of 19%, both showing improvements from the previous year. CooperVision and CooperSurgical both contributed to the revenue growth, with CooperVision seeing a 9% increase, driven by strong performance in the Americas and EMEA regions. CooperSurgical’s revenue rose by 12%, with significant growth in the fertility segment.
Looking ahead to fiscal 2025, CooperCompanies projects continued growth with expected total revenue between $4,080 million and $4,158 million, and non-GAAP EPS guidance in the range of $3.92 to $4.02. The company remains optimistic about its future, anticipating sustained success driven by strategic initiatives and market expansion.
Overall, CooperCompanies’ solid financial performance and optimistic outlook for the upcoming year demonstrate its strong position in the medical device industry, underpinned by a commitment to innovation and operational efficiency.
